New drug may shield heart surgery patients from deadly complications

NCT ID NCT07594509

Not yet recruiting Disease control Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug vericiguat can prevent serious heart and organ problems in people undergoing heart surgery. About 600 high-risk patients will receive either vericiguat plus standard care or standard care alone. The goal is to see if vericiguat reduces early complications like low cardiac output, heart injury, and major adverse events within a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vericiguat
What this could lead to: If it works, this could lead to a new standard treatment to prevent serious heart and organ damage after cardiovascular surgery.
What could go wrong: This trial hasn't started yet, and it's not a cure—it aims to reduce complications. Results may not apply to all surgery types or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIO VASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIO VASCULAR DISEASE CARDIOPULMONARY BYPASS

Contacts and locations

Locations

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.